Browse the evidence

Wound dehiscence is more prevalent among patients taking GLP-1ras for diabetes compared to those using it for weight loss.

Consideration of the indication for GLP-1ra use may be important in assessing surgical risk.

One-year discontinuation rates for GLP-1 receptor agonists can be as high as 74% in real-world studies.

Healthcare providers should be aware of the high discontinuation rates of GLP-1 RAs in real-world settings.

The percent kilocalories from carbohydrate was higher in the omnivorous group compared to the vegan group.

Omnivorous diets may provide a higher carbohydrate intake compared to vegan diets, which could influence overall energy balance.

Reduction in HbA1c was not significantly different between the high- and low-dose intervention.

Both high and low doses of produce prescriptions may be equally effective for HbA1c reduction.

L-aspartate administration led to a significant reduction in body weight, with decreases of 14.5% in HFC diet mice and 8.5% in HFC diet-induced obese mice.

L-aspartate may be considered as a potential treatment for obesity in similar dietary contexts.

Obesity has reached an epidemic scope in the United States and is a significant public health concern.

Healthcare practitioners should prioritize addressing obesity as a critical health issue.

Plastic surgery in patients with obesity is associated with higher complication rates before and after weight loss.

Surgeons should be aware of the increased risks when operating on obese patients.

The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide is $1845 and $985, respectively.

Healthcare providers should be aware of the cost implications when prescribing these medications.

Clinical trials of tirzepatide have demonstrated cardiovascular safety in high-risk patients.

Tirzepatide may be considered safe for use in patients at high cardiovascular risk.

The cardiovascular benefits of dual GLP-1/GIP receptor agonists like tirzepatide remain uncertain.

Further research is needed to clarify the cardiovascular benefits of tirzepatide.

Bariatric surgery cannot completely eliminate the possibility of weight regain and inadequate weight loss.

Patients should be informed about the potential for weight regain after surgery.

Changes in lean mass (LM) are not significantly associated with the risk of kidney outcomes (adjusted HR 0.78, 95% CI 0.58-1.06) in participants with overweight/obesity and T2DM.

Practitioners may not need to prioritize lean mass changes for kidney health in T2DM patients.

A semisupervised high-intensity interval training (HIT) intervention did not increase menstrual frequency in women with polycystic ovary syndrome (PCOS).

Practitioners should note that HIT may not be effective for improving menstrual frequency in women with PCOS.

Severe adverse effects with GLP-1 RA use are not uncommon and warrant further close monitoring.

Practitioners should closely monitor patients for severe adverse effects when initiating GLP-1 RA therapy.

There is an ongoing debate over the role of pharmacotherapy versus interventional approaches in treating obesity and MASLD in liver transplantation.

Clinicians should stay informed about evolving treatment options for obesity and MASLD.

Experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce.

Further research is needed to establish the efficacy and safety of GLP-1 agonists in this specific population.

The use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes.

Healthcare providers should be cautious when prescribing semaglutide to patients with a history of AOM use, as they may not achieve optimal weight loss.

There is a need for a dedicated trial to examine the benefits of semaglutide in type 1 diabetes.

Further research is warranted to validate the effects of semaglutide in type 1 diabetes.

Tirzepatide has a generally safe profile with possible mild-to-moderate gastrointestinal side effects.

Healthcare providers should monitor patients for gastrointestinal side effects when prescribing tirzepatide.

Neither chia flour nor whey protein supplementation elicited an enhanced effect on fat-free mass (FFM) and strength gains after an 8-week resistance training program.

Supplementing with chia flour or whey protein does not provide additional benefits for body composition or strength in young men already consuming a high protein diet.

Global consumption of ultra-processed foods (UPFs) has increased dramatically.

Practitioners should be aware of the rising trend in UPF consumption.

No additional benefits were observed for ∑MT.

Practitioners should note that increasing volume may not benefit all measures of training outcomes.

There are inadequacies in the measures used to qualify obesity.

Practitioners should be aware of the limitations in current obesity measures when assessing health risks.

There is a need to determine intermediate factors and mechanisms connecting excess adiposity and health.

Identifying these factors can enhance targeted interventions for obesity-related health issues.